Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Apr 27, 2018
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Based on current medical literature, the risk of hepatitis B reactivation is high after allogenic stem cell transplant and can be a major problem in the post-transplant population, leading to increased morbidity and mortality. Additionally, many people in the general population and transplant population do not achieve immunity against hepatitis B with the first vaccination series and may require repeat series.
Currently, it is unclear as to what percentage of post-transplant patients have a failed or delayed immunity against hepatitis B and how many vaccine series it may take to eventually...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • 1. Patient must have received at least one dose of the hepatitis B vaccine and been enrolled in the following NHLBI protocols: 99-H-0050, 10-H-0154, and 08-H-0046.
- • 2. Post-vaccination titers must be available for patients included in the study.
- EXCLUSION CRITERIA:
- • 1. No post-vaccination titers available.
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Richard W Childs, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials